Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Common Equity (2021 - 2025)

InMed Pharmaceuticals (INM) has 5 years of Common Equity data on record, last reported at $9.6 million in Q4 2025.

  • For Q4 2025, Common Equity rose 55.09% year-over-year to $9.6 million; the TTM value through Dec 2025 reached $9.6 million, up 55.09%, while the annual FY2025 figure was $13.4 million, 45.93% up from the prior year.
  • Common Equity reached $9.6 million in Q4 2025 per INM's latest filing, down from $11.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $15.2 million in Q3 2021 and bottomed at -$9.6 million in Q3 2023.
  • Average Common Equity over 5 years is $9.9 million, with a median of $11.1 million recorded in 2022.
  • Peak YoY movement for Common Equity: plummeted 187.01% in 2023, then surged 187.65% in 2024.
  • A 5-year view of Common Equity shows it stood at $14.2 million in 2021, then grew by 1.18% to $14.3 million in 2022, then fell by 10.9% to $12.8 million in 2023, then tumbled by 51.6% to $6.2 million in 2024, then soared by 55.09% to $9.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $9.6 million in Q4 2025, $11.6 million in Q3 2025, and $13.4 million in Q2 2025.